Skip to content

An evaluation of Motivational (MI) plus Cognitive Therapy (CBT) for Schizophrenia and Substance Misuse

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN14404480
Enrollment
400
Registered
2003-09-01
Start date
2004-10-03
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental and behavioural disorder Mental and Behavioural Disorders Subtance abuse

Interventions

The experimental treatment (MI plus CBT) will consist of motivational interviewing to increase motivation to reduce substance use
CBT for help with both substance use reduction and symptom management
and relapse prevention strategies. Patients randomised to receive MI plus CBT will be offered up to 26 sessions over 12 months with treatment being located at home or clinic according to the patient's

Sponsors

University of Manchester (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM IV) diagnostic criteria for schizophrenia, schizophreniform or schizoaffective disorder 2. Recorded contact and treatment from mental health services at the point of recruitment 3. Prescribed anti-psychotic medication 4. Alcohol use exceeding 28 units for males, 21 units for females on at least half the weeks in the previous 3 months 5. DSM IV diagnosis of drug and/or alcohol dependence or abuse 6. No significant history of organic factors implicated in the aetiology of psychotic symptoms 7. English speaking 8. Informed patient consent 9. Having a fixed abode

Exclusion criteria

Exclusion criteria: See inclusion criteria

Design outcomes

Secondary

MeasureTime frame
Added as of 6 February 2007: Measures of symtomatology, relapses, substance misuse and health economic analyses.

Primary

MeasureTime frame
Either readmission to hospital for reason related to psychosis or death from any cause/not admitted to hospital in the 12 month post-treatment period.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 30, 2026